To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva (Progress)
Primary Purpose
Fibrodysplasia Ossificans Progressiva (FOP)
Status
Recruiting
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
INCB000928
placebo
Sponsored by

About this trial
This is an interventional treatment trial for Fibrodysplasia Ossificans Progressiva (FOP) focused on measuring fibrodysplasia ossificans progressiva (FOP), heterotopic ossification
Eligibility Criteria
Inclusion Criteria:
- Female and male adults and adolescents ≥ 12 years of age with a diagnosis of FOP.
- Willingness to avoid pregnancy or fathering children based on the criteria below.
- Willing and able to undergo low-dose WBCT (excluding the head) imaging without requiring intubation.
- Further inclusion criteria apply.
Exclusion Criteria:
- Pregnant or breast-feeding.
- CAJIS score ≥ 24.
- FOP disease severity that in the investigator's opinion precludes participation.
- Any clinically significant medical condition other than FOP that would, in the investigator's judgment, interfere with full participation in the study, pose a significant risk to the participant, or interfere with interpretation of study data.
- Chronic or current active infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment.
- HIV, HBV, or HCV infection. Note:
- Further exclusion criteria apply.
Sites / Locations
- University of California San Francisco Medical Center
- Mayo ClinicRecruiting
- Children'S Hospital of PhiladelphiaRecruiting
- University of Pennsylvania HospitalRecruiting
- Hospital Italiano de Buenos Aires
- Royal North Shore HospitalRecruiting
- Murdoch Children'S Research InstituteRecruiting
- Westmead Hospital
- Albert Einstein Israelite Hospital
- Toronto General HospitalRecruiting
- Hospital San Juan de DiosRecruiting
- Beijing Childrens Hospital Capital Medical UniversityRecruiting
- Beijing Children'S Hospital, Capital Medical UniversityRecruiting
- Shanghai Childrens Medical CenterRecruiting
- Childrens Hospital of Fudan UniversityRecruiting
- Ap-Hp Hopital LariboisiereRecruiting
- Hospital NeckerRecruiting
- Universitatsklinikum Koeln
- Ospedale Pediatrico G. Gaslini
- Fondazione Policlinico Universitario Agostino Gemelli Irccs
- Seoul National University HospitalRecruiting
- Instituto Nacional de Rehabilitacion Luis Guillermo Ibarra
- Amsterdam Umc
- Starship Childrens Hospital
- Centro Hospitalar de Lisboa Norte E.P.E. - Hospital de Santa Maria
- Irkutsk State Medical University
- Nasonova Research Institute of Rheumatology
- Saint Petersburg State Pediatric Medical University
- Red Cross Children'S HospitalRecruiting
- Hospital Universitario Ramon Y CajalRecruiting
- Ege University School of Medicine
- Royal Manchester Childrens Hospital - Department of Paediatric Endocrinology
- Royal National Orthopaedic Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Group A: INCB000928
Group B: Placebo followed by INCB000928
Arm Description
Participants will receive INCB000928 for 24 weeks (double-blind period). Participants who complete the double-blind period will continue into open-label extension period for an additional 52 weeks.
Participants will receive placebo for 24 weeks (double-blind period). Participants who completed the double-blind period will receive INCB000928 in the 52 week open-label extension period.
Outcomes
Primary Outcome Measures
Double Blind Period: Total volume of new heterotopic ossification (HO)
HO will be assessed by low dose whole-body computed tomography (WBCT) (excluding the head) compared to baseline during the double-blind period.
Secondary Outcome Measures
Double-blind Period: Total number of new flares
Defined as number of new flares compared to baseline during the double-blind period.
Double-blind Period: Proportion of participants with a clinically meaningful improvement in the flare-related symptoms
Flare related symptoms will be assessed by via an electronic PRO during the double-blind period.
Number of Participants with Treatment Emergent Adverse Events (TEAE)
Defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05090891
Brief Title
To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva
Acronym
Progress
Official Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva
Study Type
Interventional
2. Study Status
Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 5, 2022 (Actual)
Primary Completion Date
December 30, 2023 (Anticipated)
Study Completion Date
December 2, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Incyte Corporation
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This Phase 2, Randomized, Double-Blind, Placebo-Controlled Study is intended to evaluate the Efficacy, Safety, and Tolerability and PK of INCB000928 administered to participants with a clinical diagnosis of fibrodysplasia ossificans progressiva (FOP).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fibrodysplasia Ossificans Progressiva (FOP)
Keywords
fibrodysplasia ossificans progressiva (FOP), heterotopic ossification
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
60 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Group A: INCB000928
Arm Type
Experimental
Arm Description
Participants will receive INCB000928 for 24 weeks (double-blind period). Participants who complete the double-blind period will continue into open-label extension period for an additional 52 weeks.
Arm Title
Group B: Placebo followed by INCB000928
Arm Type
Placebo Comparator
Arm Description
Participants will receive placebo for 24 weeks (double-blind period). Participants who completed the double-blind period will receive INCB000928 in the 52 week open-label extension period.
Intervention Type
Drug
Intervention Name(s)
INCB000928
Other Intervention Name(s)
INB000928 will be administered QD orally
Intervention Description
INCBG000928 will be administered QD orally.
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
placebo will be administered QD orally
Primary Outcome Measure Information:
Title
Double Blind Period: Total volume of new heterotopic ossification (HO)
Description
HO will be assessed by low dose whole-body computed tomography (WBCT) (excluding the head) compared to baseline during the double-blind period.
Time Frame
Week 24
Secondary Outcome Measure Information:
Title
Double-blind Period: Total number of new flares
Description
Defined as number of new flares compared to baseline during the double-blind period.
Time Frame
Baseline, Week 12 and Week 24
Title
Double-blind Period: Proportion of participants with a clinically meaningful improvement in the flare-related symptoms
Description
Flare related symptoms will be assessed by via an electronic PRO during the double-blind period.
Time Frame
Baseline, Week 12 and Week 24
Title
Number of Participants with Treatment Emergent Adverse Events (TEAE)
Description
Defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug.
Time Frame
Up to 80 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
12 Years
Maximum Age & Unit of Time
99 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Female and male adults and adolescents ≥ 12 years of age with a diagnosis of FOP.
Willingness to avoid pregnancy or fathering children based on the criteria below.
Willing and able to undergo low-dose WBCT (excluding the head) imaging without requiring intubation.
Further inclusion criteria apply.
Exclusion Criteria:
Pregnant or breast-feeding.
CAJIS score ≥ 24.
FOP disease severity that in the investigator's opinion precludes participation.
Any clinically significant medical condition other than FOP that would, in the investigator's judgment, interfere with full participation in the study, pose a significant risk to the participant, or interfere with interpretation of study data.
Chronic or current active infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment.
HIV, HBV, or HCV infection. Note:
Further exclusion criteria apply.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Incyte Corporation Call Center (US)
Phone
1.855.463.3463
Email
medinfo@incyte.com
First Name & Middle Initial & Last Name or Official Title & Degree
Incyte Corporation Call Center (ex-US)
Phone
+800 00027423
Email
eumedinfo@incyte.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kurt Brown, MD
Organizational Affiliation
Incyte Corporation
Official's Role
Study Director
Facility Information:
Facility Name
University of California San Francisco Medical Center
City
San Francisco
State/Province
California
ZIP/Postal Code
94143
Country
United States
Individual Site Status
Withdrawn
Facility Name
Mayo Clinic
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States
Individual Site Status
Recruiting
Facility Name
Children'S Hospital of Philadelphia
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Individual Site Status
Recruiting
Facility Name
University of Pennsylvania Hospital
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Individual Site Status
Recruiting
Facility Name
Hospital Italiano de Buenos Aires
City
Buenos Aires
ZIP/Postal Code
C1199ABD
Country
Argentina
Individual Site Status
Not yet recruiting
Facility Name
Royal North Shore Hospital
City
St Leonards
State/Province
New South Wales
ZIP/Postal Code
02065
Country
Australia
Individual Site Status
Recruiting
Facility Name
Murdoch Children'S Research Institute
City
Parkville
State/Province
Victoria
ZIP/Postal Code
03052
Country
Australia
Individual Site Status
Recruiting
Facility Name
Westmead Hospital
City
Westmead
ZIP/Postal Code
02145
Country
Australia
Individual Site Status
Withdrawn
Facility Name
Albert Einstein Israelite Hospital
City
San Paolo
ZIP/Postal Code
05652-900
Country
Brazil
Individual Site Status
Not yet recruiting
Facility Name
Toronto General Hospital
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 2C4
Country
Canada
Individual Site Status
Recruiting
Facility Name
Hospital San Juan de Dios
City
Santiago Region Metropolitana
Country
Chile
Individual Site Status
Recruiting
Facility Name
Beijing Childrens Hospital Capital Medical University
City
Beijing
ZIP/Postal Code
100045
Country
China
Individual Site Status
Recruiting
Facility Name
Beijing Children'S Hospital, Capital Medical University
City
Shanghai
ZIP/Postal Code
200065
Country
China
Individual Site Status
Recruiting
Facility Name
Shanghai Childrens Medical Center
City
Shanghai
ZIP/Postal Code
200127
Country
China
Individual Site Status
Recruiting
Facility Name
Childrens Hospital of Fudan University
City
Shanghai
ZIP/Postal Code
201102
Country
China
Individual Site Status
Recruiting
Facility Name
Ap-Hp Hopital Lariboisiere
City
Paris
ZIP/Postal Code
75010
Country
France
Individual Site Status
Recruiting
Facility Name
Hospital Necker
City
Paris
ZIP/Postal Code
75015
Country
France
Individual Site Status
Recruiting
Facility Name
Universitatsklinikum Koeln
City
Koln
ZIP/Postal Code
50937
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Ospedale Pediatrico G. Gaslini
City
Genova
ZIP/Postal Code
16147
Country
Italy
Individual Site Status
Withdrawn
Facility Name
Fondazione Policlinico Universitario Agostino Gemelli Irccs
City
Rome
ZIP/Postal Code
00137
Country
Italy
Individual Site Status
Not yet recruiting
Facility Name
Seoul National University Hospital
City
Seoul
ZIP/Postal Code
03080
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Instituto Nacional de Rehabilitacion Luis Guillermo Ibarra
City
Tlapan
ZIP/Postal Code
14389
Country
Mexico
Individual Site Status
Not yet recruiting
Facility Name
Amsterdam Umc
City
Amsterdam
ZIP/Postal Code
1081 HV
Country
Netherlands
Individual Site Status
Not yet recruiting
Facility Name
Starship Childrens Hospital
City
Auckland
ZIP/Postal Code
01023
Country
New Zealand
Individual Site Status
Not yet recruiting
Facility Name
Centro Hospitalar de Lisboa Norte E.P.E. - Hospital de Santa Maria
City
Lisboa
ZIP/Postal Code
1649-035
Country
Portugal
Individual Site Status
Not yet recruiting
Facility Name
Irkutsk State Medical University
City
Irkutsk
ZIP/Postal Code
664003
Country
Russian Federation
Individual Site Status
Withdrawn
Facility Name
Nasonova Research Institute of Rheumatology
City
Moscow
ZIP/Postal Code
115478
Country
Russian Federation
Individual Site Status
Withdrawn
Facility Name
Saint Petersburg State Pediatric Medical University
City
St. Petersburg
ZIP/Postal Code
194100
Country
Russian Federation
Individual Site Status
Withdrawn
Facility Name
Red Cross Children'S Hospital
City
Cape Town
ZIP/Postal Code
07700
Country
South Africa
Individual Site Status
Recruiting
Facility Name
Hospital Universitario Ramon Y Cajal
City
Madrid
ZIP/Postal Code
28034
Country
Spain
Individual Site Status
Recruiting
Facility Name
Ege University School of Medicine
City
Izmir
ZIP/Postal Code
35100
Country
Turkey
Individual Site Status
Not yet recruiting
Facility Name
Royal Manchester Childrens Hospital - Department of Paediatric Endocrinology
City
Manchester
ZIP/Postal Code
M13 9PL
Country
United Kingdom
Individual Site Status
Withdrawn
Facility Name
Royal National Orthopaedic Hospital
City
Stanmore
ZIP/Postal Code
HA7 4LP
Country
United Kingdom
Individual Site Status
Not yet recruiting
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
IPD Sharing Time Frame
Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.
IPD Sharing Access Criteria
Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.
IPD Sharing URL
https://www.incyte.com/our-company/compliance-and-transparency
Learn more about this trial
To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva
We'll reach out to this number within 24 hrs